Please login to the form below

Not currently logged in
Email:
Password:

Valid Insight receives Queen’s Awards for Enterprise

Specialist in life sciences market access

vi

Valid Insight has received a Queen’s Award for Enterprise, an accolade presented to companies demonstrating outstanding results in their field.

First established in 2016, Valid Insight provides consultancy services to pharma, biotech and the medical device industry on global market access issues.

The recognition for Valid Insight follows its work with client firms across Europe, Switzerland, the USA and Japan involved in the development and commercialisation of medical treatments, diagnostics and devices across multiple therapy areas.

Steve Bradshaw

Steve Bradshaw

“We are honoured to receive the Queen’s Award for Enterprise in International Trade. We compete against a strong set of consultancy firms on a global level and to win this award means that what we are doing is world class,” said Steve Bradshaw, founder and managing director, Valid Insight.

“From the outset, our strategy was to create a competitive, truly differentiated, global strategy consulting firm with a virtual working model to attract the best talent irrespective of geography.

“We provide world-class expertise and strategic consulting solutions and tools to give the highest level of certainty around our clients’ most critical business decisions, wherever they are based.

“To win the Queen’s Award strengthens our reputation as a leader in the field and we look forward to an exciting future.”

17th June 2019

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics